DENVER, Colo. (247marketnews.com) -- NextCure (NASDAQ:NXTC) is making one of the most dramatic strategic pivots seen in biotechnology this year, announcing an all-stock merger with privately held Avere Therapeutics that will effectively transform the company into a new publicly traded autoimmune disease developer. Upon closing, the combined company will operate as Avere Therapeutics and trade under the new NASDAQ ticker AVRX, shifting its primary focus from oncology to inflammatory diseases driven by the IL-23 pathway.
The transaction is accompanied by a massive $320 million concurrent private financing, led by an elite syndicate of healthcare investors including Fairmount, Hansoh Pharmaceutical, General Atlantic, Wellington Management, Venrock Healthcare Capital Partners, Janus Henderson, T. Rowe Price-advised funds, RTW Investments, Redmile, Logos Capital, and others. Management expects the financing to provide sufficient capital to fund AVR-001 through multiple major clinical milestones, including a Phase 2b psoriasis readout, initiation of a Phase 3 psoriasis study, and the launch of a Phase 2b ulcerative colitis trial.
At the center of the story is AVR-001, Avere's once-weekly oral IL-23 receptor antagonist designed to compete in one of the pharmaceutical industry's fastest-growing inflammatory disease markets. Unlike injectable biologics, AVR-001 is engineered as an oral cyclic peptide with an approximately 100-hour half-life, allowing convenient once-weekly dosing. Early Phase 1b psoriasis data generated by Hansoh Pharmaceutical demonstrated encouraging clinical activity, with cross-trial comparisons suggesting efficacy that may be competitive with first-generation daily oral IL-23 therapies despite substantially less frequent dosing. While cross-trial comparisons have important limitations, the data were strong enough to support rapid advancement into global mid-stage studies.
The merger also brings together a management team with a proven commercialization and value-creation track record. Avere's leadership previously guided Akero Therapeutics from its pre-IPO stage through its acquisition by Novo Nordisk in a deal valued at up to $5.2 billion, giving investors confidence that the company has experience navigating both clinical development and strategic transactions. Separately, Avere recently secured an exclusive licensing agreement with Hansoh outside Greater China that includes $120 million in upfront payments and up to $2.18 billion in potential development and commercial milestones, further validating AVR-001's perceived commercial potential.
For existing NextCure shareholders, the transaction represents a near-complete corporate transformation rather than a continuation of its oncology strategy. Following closing, current NextCure shareholders are expected to own approximately 1.21% of the combined company, while Avere shareholders and financing participants will control approximately 98.79%. To provide additional potential upside, legacy NextCure investors will also receive contingent value rights (CVRs) tied to future monetization of NextCure's remaining oncology assets for two years after closing.
The deal reflects a broader trend across biotechnology, where public companies increasingly serve as capital-efficient vehicles for promising private clinical-stage assets. With substantial funding, experienced leadership, encouraging early clinical data, and a differentiated once-weekly oral therapy targeting validated IL-23 biology, the new Avere Therapeutics enters the public markets with a clear development roadmap. As always, meaningful clinical, regulatory, and commercial risks remain, but investors now have several clearly defined catalysts to watch beginning with Phase 2b development expected to start in early 2027.
Sources
Business Wire – NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing: https://www.businesswire.com/
Avere Therapeutics: https://www.averetx.com/
NextCure Investor Relations: https://www.nextcure.com/
ClinicalTrials.gov (IL-23 Clinical Development): https://clinicaltrials.gov/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.